Profitability Metrics

Gross Margin
33.81%
Operating Margin
8.52%
Net Margin
27.13%

Efficiency Metrics

Revenue per Expense Ratio
1.09
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
18.69%
Income Tax Rate
487.55%
EPS
1.0800000000

Balance Sheet Analysis

Current Ratio
0.60
Cash Ratio
0.00
Working Capital
$-100.26M
Debt to Equity
0.85
Debt to Assets
32.81%
Equity Ratio
38.45%

Cash Flow Analysis

Operating Cash Flow Ratio
24.05%
Free Cash Flow Ratio
4.76%
CapEx to Revenue
19.29%
Dividends Paid
$125.00M
Stock Buybacks
No buybacks
Total Shareholder Returns
$125.00M
Cash Position Change
-99.42%

Key Takeaways (2023 FY)

  • Revenue declined by 15.381021183496%, indicating potential market challenges
  • Maintained positive net income growth despite revenue changes

Detailed Growth Metrics

Core Performance

Revenue
-15.38%
Net Income
257.15%
EPS
248.39%
Operating Income
-43.96%

Operational Efficiency

R&D Expenses
0.00%
SG&A Expenses
-36.03%
Operating Cash Flow
-44.21%
Free Cash Flow
-72.64%

Balance Sheet Health

Assets
-5.17%
Debt
-12.41%
Book Value per Share
11.52%
Inventory
17.44%

Shareholder Returns

Dividends per Share
0.00%
Shares Outstanding
2.93%

Long Term Trends

3Y Revenue/Share
26.56%
5Y Revenue/Share
1.96%
3Y Dividend/Share
0.00%
5Y Dividend/Share
356.18%